SCHEMBL4200130

SCHEMBL4200130

CC(CC1CCCCC1)NCc1ccccc1NS(=O)(=O)c1ccc(-n2cccc2)nc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
LMNA P02545 6/20 0.38
POLB P06746 3/20 0.38
ALDH1A1 P00352 6/20 0.37
MAPT P10636 7/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
TP53 P04637 3/20 0.34
THRB P10828 2/20 0.34
TSHR P16473 1/20 0.32
MLNR O43193 1/20 0.32
PTGES2 Q9H7Z7 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190576 0.99 KDM4E (0.43) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4200151 0.91 KDM4E (0.41) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4197301 0.90 KDM4E (0.40) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4197346 0.90 KDM4E (0.44) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4191244 0.90 KDM4E (0.44) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4194642 0.89 KDM4E (0.43) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4192408 0.86 ALDH1A1 (0.44) KDM4EPKMLMNAALDH1A1SMN1; SMN2
SCHEMBL4202288 0.86 PKM (0.50) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4192418 0.86 KDM4E (0.43) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4185823 0.86 KDM4E (0.43) KDM4EPKMLMNAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
CN-101203504-B Antimicrobial agents RANBAXY LAB LTD 2012-11-14 CN claimed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
CN-101203504-A Antimicrobial agents RANBAXY LAB LTD (IN) 2008-06-18 CN claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
CN-101203504-B Antimicrobial agents RANBAXY LAB LTD 2012-11-14 CN disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
CN-101203504-A Antimicrobial agents RANBAXY LAB LTD (IN) 2008-06-18 CN disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 KDM4E 3328/4885PKM 1855/4885LMNA 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.